NTC's Phase II Study Shows Promising Outcomes for Innovative Drug to Treat Bacterial Conjunctivitis NTC announces positive findings from its Phase II MIRAKLE study, showcasing the effectiveness of NTC014 in treating bacterial conjunctivitis in adults.

NTC's Phase II Study Shows Promising Outcomes for Innovative Drug to Treat Bacterial Conjunctivitis #Italy #Milan #NTC014 #bacterial_conjunctivitis #Phase_II_Trial

NTC Unveils Promising Results from Phase II Mirakle Study for Innovative Bacterial Conjunctivitis Drug NTC, a global pharmaceutical company based in Italy, has reported positive outcomes from its Phase II MIRAKLE study, which evaluates NTC014 against bacterial conjunctivitis.

NTC Unveils Promising Results from Phase II Mirakle Study for Innovative Bacterial Conjunctivitis Drug #Italy #Milan #NTC014 #bacterial_conjunctivitis #NTC

NTC Reports Promising Phase II Results for Innovative Bacterial Conjunctivitis Treatment NTC unveils encouraging Phase II findings for a novel treatment, NTC014, targeting bacterial conjunctivitis, marking a step forward in eye care.

NTC Reports Promising Phase II Results for Innovative Bacterial Conjunctivitis Treatment #Italy #Milan #NTC014 #bacterial_conjunctivitis #Eye_Care

Innovative Phase II Study Mirakle Shows Promising Results for Bacterial Conjunctivitis Treatment NTC's Phase II Mirakle study reveals positive outcomes for an innovative eye drop treatment for bacterial conjunctivitis in adults. Find out more!

Innovative Phase II Study Mirakle Shows Promising Results for Bacterial Conjunctivitis Treatment #Italy #Milan #NTC014 #bacterial_conjunctivitis #Mirakle_study